Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement

Edito’s Note:  VIVUS, Inc. (NASDAQ:VVUS),  Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN)

VIVUS, Inc. (NASDAQ:VVUS)VIVUS QSYMIA PATENTS: APPEARANCE OF ONGOING AND SYSTEMATIC INEQUITABLE CONDUCT BEFORE THE USPTO (World News Report)
Earlier today RFD IP Business Services (“RFD”) released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc. (NASDAQ:VVUS) and the patents that protect its approved drug, Qsymia(R) (fixed dose combinations of phentermine and topiramate). What is new in the Inequitable Conduct Report? The report exposes the tension between, on the one hand, admissions by Vivus attorneys at Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC (“Mintz Levin”) that the company’s earliest Qsymia patents do not teach how to use low doses of topiramate (15 to 50 mg), while simultaneously trying to obtain claims from these early patents that cover doses of topiramate from 5 to 1000 mg.

News Buzz: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Pandora Media Inc (NYSE:P) (SBWire)
Earnings of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in the second quarter of 2013 at 17 cents per share were higher than the earnings in the previous year. The firm’s revenues of $68.9 million were 213% higher than the previous year for the same period thanks to $65 million milestone payment from partner Eisai for Belviq. The pharmaceutical firm had launched the obesity drug, Belviq in June 2013 and the drug has recorded sales of $1.3 million which is evident from the 12,500 prescriptions written for it until July 19. The firm also got $0.5 million milestone payment from Eisai submission of New Drug in Canada for Belviq.

Array says Amgen ends agreement, to cut 20 percent jobs (Reuters)
Array Biopharma said it would cut 20 percent of its workforce as  Amgen, Inc. (NASDAQ:AMGN) plans to end an agreement to develop and market Array’s drug to treat Type 2 diabetes. Array shares fell as much as 7 percent to $6.12 in trading after the bell. The company said it would record a one-time restructuring charge of $2.7 million in the first quarter of fiscal 2014. Array and  Amgen, Inc. (NASDAQ:AMGN) entered into the agreement in December 2009, under which Array received an upfront payment of $60 million and milestone payments of $8.5 million.

Amgen ‘neck and neck’ with competitors in race for new anti-cholesterol drugs approval (Med City News)
In one of the most closely-watched medical races of all time, Amgen and rival pharmaceutical companies are chasing approval for new anti-cholesterol drugs that have the potential to be blockbusters. Cardiologists see them as the single most promising class of drugs currently in development, said Dr. Steven Nissen, the department chair of cardiovascular medicine at the Cleveland Clinic. For its new cholesterol-fighting drug, AMG 145, Thousand Oaks-based Amgen expects to have data from its pre-marketing clinical trial period available in early 2014.

2 Biotechs Aim To Capitalize On The Treatment Of Melanoma (Seeking Alpha)
Data from key trials of experimental treatments for melanoma brings good news for those affected by this deadly form of cancer. Following the disappointment from Vical’s (VICL) failed Phase 3 study, the development of melanoma treatments offer investors a solid opportunity with two different stocks.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!